Genscript Biotech Corporation
1548
Κατάταξη σε μετοχές
#2128
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Τιμή μετοχής
$4.28
Κεφαλαιοποίηση
$9.61B
Αλλαγή (1 ημέρα)
0.36%
Αλλαγή (1 έτος)
107.31%
Χώρα
HK
Εμπόριο Genscript Biotech Corporation (1548)
Κατηγορία
Healthcare
EPS για Genscript Biotech Corporation (1548)
EPS στις June 2026 TTM: $-0.30
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Genscript Biotech Corporation, το τρέχον EPS της εταιρείας (TTM) είναι $-0.30. Στο τέλος του 2023, η εταιρεία είχε EPS $-0.05, μείωση σε σύγκριση με το EPS του 2022 που ήταν $-0.11.
Ιστορικό EPS της Genscript Biotech Corporation από 2013 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-0.30 | 900.00% |
| 2024 | $-0.03 | -31.57% |
| 2023 | $-0.05 | -58.82% |
| 2022 | $-0.11 | -38.89% |
| 2021 | $-0.18 | 63.64% |
| 2020 | $-0.11 | 110.33% |
| 2019 | $-0.05 | -543.22% |
| 2018 | $0.01 | -22.37% |
| 2017 | $0.02 | -3.18% |
| 2016 | $0.02 | 6.80% |
| 2015 | $0.01 | 182.69% |
| 2014 | $0.01 | 36.84% |
| 2013 | 0.00 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $17.32 | -5,873.33% |
US
|
|
| $-7.98 | 2,560.00% |
US
|
|
| $-5.29 | 1,663.33% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -9,346.67% |
NL
|
